Covered recipient · General Payments record
HOPE L O'BRIEN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology with Special Qualifications in Child Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$60,446.42
83 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,593.75 | 17 |
| Honoraria | $7,200.00 | 1 |
| Consulting Fee | $5,610.00 | 1 |
| Food and Beverage | $2,533.32 | 50 |
| Travel and Lodging | $1,474.55 | 9 |
| Education | $34.80 | 5 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | $45,791.25 | 45 |
| BioDelivery Sciences International, Inc. | $7,810.26 | 11 |
| Amgen Inc. | $6,236.60 | 4 |
| AbbVie Inc. | $254.20 | 13 |
| Teva Pharmaceuticals USA, Inc. | $155.81 | 4 |
| SK Life Science, Inc. | $114.63 | 1 |
| Allergan, Inc. | $47.07 | 3 |
| Lilly USA, LLC | $36.60 | 2 |
Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HOPE L O'BRIEN
NPI 1972704138 · CMS profile ID 647248
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology
CINCINNATI, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1972704138?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HOPE L O'BRIEN, NPI 1972704138, CMS profile ID 647248. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972704138?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). HOPE L O'BRIEN, NPI 1972704138, CMS profile ID 647248. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972704138?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- HOPE L O'BRIEN, NPI 1972704138, CMS profile ID 647248, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–83 of 83 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1972704138?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
83 matching records · $60,446.42 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–83 of 83.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Biohaven Pharmaceuticals, Inc. | $45.67 | 09/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581103 | CMS |
| Biohaven Pharmaceuticals, Inc. | $6.18 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581097 | CMS |
| Amgen Inc. | $19.10 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825356661 | CMS |
| Allergan, Inc. | $11.99 | 08/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792892939 | CMS |
| Biohaven Pharmaceuticals, Inc. | $3,000.00 | 08/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581093 | CMS |
| Biohaven Pharmaceuticals, Inc. | $125.00 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581095 | CMS |
| Lilly USA, LLC | $17.90 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818550497 | CMS |
| Biohaven Pharmaceuticals, Inc. | $2,000.00 | 08/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581083 | CMS |
| Biohaven Pharmaceuticals, Inc. | $33.33 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581085 | CMS |
| Biohaven Pharmaceuticals, Inc. | $3,000.00 | 08/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581087 | CMS |
| Biohaven Pharmaceuticals, Inc. | $37.52 | 08/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581089 | CMS |
| Biohaven Pharmaceuticals, Inc. | $119.29 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581091 | CMS |
| AbbVie Inc. | $6.96 | 08/09/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795390333 | CMS |
| AbbVie Inc. | $6.96 | 08/09/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795390339 | CMS |
| AbbVie Inc. | $6.96 | 08/09/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795390343 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.34 | 08/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839502625 | CMS |
| Biohaven Pharmaceuticals, Inc. | $3,000.00 | 07/28/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581079 | CMS |
| Biohaven Pharmaceuticals, Inc. | $125.00 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581081 | CMS |
| AbbVie Inc. | $11.14 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795390327 | CMS |
| Biohaven Pharmaceuticals, Inc. | $124.64 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581077 | CMS |
| Biohaven Pharmaceuticals, Inc. | $23.96 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581075 | CMS |
| Teva Pharmaceuticals USA, Inc. | $104.90 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839502559 | CMS |
| Biohaven Pharmaceuticals, Inc. | $50.79 | 06/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581063 | CMS |
| Biohaven Pharmaceuticals, Inc. | $51.56 | 06/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581065 | CMS |
| Biohaven Pharmaceuticals, Inc. | $66.18 | 06/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581067 | CMS |
| Biohaven Pharmaceuticals, Inc. | $495.20 | 06/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581069 | CMS |
| Biohaven Pharmaceuticals, Inc. | $365.00 | 06/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581071 | CMS |
| Biohaven Pharmaceuticals, Inc. | $145.12 | 06/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581073 | CMS |
| Biohaven Pharmaceuticals, Inc. | $100.64 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581059 | CMS |
| Biohaven Pharmaceuticals, Inc. | $39.94 | 06/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581061 | CMS |
| Biohaven Pharmaceuticals, Inc. | $2,000.00 | 06/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852581057 | CMS |
| Amgen Inc. | $593.75 | 03/31/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825356657 | CMS |
| Amgen Inc. | $5,610.00 | 03/10/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825356653 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $161,113.60 | 86 |
| PY2024 | Recipient | $11,400.00 | 3 |
| PY2024 | Principal investigator | $116,946.76 | 37 |
| PY2023 | Recipient | $2,500.78 | 3 |
| PY2023 | Principal investigator | $126,205.18 | 37 |
| PY2022 | Recipient | $18,393.00 | 4 |
| PY2022 | Principal investigator | $56,150.04 | 11 |
| PY2019 | Principal investigator | $3,070.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
86 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 12/31/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202534257 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $14,750.00 | 12/10/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine | No dispute reported | 06/30/2026 | 1232647310 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $2,000.00 | 12/10/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine | No dispute reported | 06/30/2026 | 1232647314 |
| Principal investigator 1 | ABBVIE INC. | $299.70 | 12/04/2025 | Non-covered Recipient Entity HOPE OBRIEN DBA HEADACHE CENTER OF HOPE LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202527500 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $2,000.00 | 11/14/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine | No dispute reported | 06/30/2026 | 1232647308 |
| Principal investigator 1 | Merz Pharmaceuticals, LLC | $14,750.00 | 11/14/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine | No dispute reported | 06/30/2026 | 1232647312 |
| Principal investigator 1 | ABBVIE INC. | $1,300.00 | 11/04/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202520169 |
| Principal investigator 1 | ABBVIE INC. | $4,344.84 | 11/04/2025 | Non-covered Recipient Entity HOPE OBRIEN DBA HEADACHE CENTER OF HOPE LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202521181 |
| Principal investigator 1 | Ipsen Innovation | $86.80 | 10/27/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289642 |
| Principal investigator 1 | Ipsen Innovation | $1,388.10 | 10/27/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289646 |
| Principal investigator 1 | Ipsen Innovation | $86.80 | 10/27/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289694 |
| Principal investigator 1 | Ipsen Innovation | $2,623.04 | 10/27/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289700 |
| Principal investigator 1 | Ipsen Innovation | $978.81 | 10/27/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289708 |
| Principal investigator 1 | Ipsen Innovation | $978.81 | 10/27/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289726 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 10/10/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289638 |
| Principal investigator 1 | Ipsen Innovation | $1,000.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289634 |
| Principal investigator 1 | Ipsen Innovation | $86.80 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289636 |
| Principal investigator 1 | Ipsen Innovation | $86.80 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289640 |
| Principal investigator 1 | Ipsen Innovation | $500.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289644 |
| Principal investigator 1 | Ipsen Innovation | $900.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289648 |
| Principal investigator 1 | Ipsen Innovation | $1,388.10 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289650 |
| Principal investigator 1 | Ipsen Innovation | $350.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289652 |
| Principal investigator 1 | Ipsen Innovation | $800.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289654 |
| Principal investigator 1 | Ipsen Innovation | $86.80 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289656 |
| Principal investigator 1 | Ipsen Innovation | $978.81 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289658 |
| Principal investigator 1 | Ipsen Innovation | $3,000.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289660 |
| Principal investigator 1 | Ipsen Innovation | $100.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289662 |
| Principal investigator 1 | Ipsen Innovation | $3,393.39 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289664 |
| Principal investigator 1 | Ipsen Innovation | $63.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289666 |
| Principal investigator 1 | Ipsen Innovation | $1,550.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289668 |
| Principal investigator 1 | Ipsen Innovation | $86.80 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289670 |
| Principal investigator 1 | Ipsen Innovation | $100.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289672 |
| Principal investigator 1 | Ipsen Innovation | $86.80 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289674 |
| Principal investigator 1 | Ipsen Innovation | $800.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289676 |
| Principal investigator 1 | Ipsen Innovation | $2,350.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289678 |
| Principal investigator 1 | Ipsen Innovation | $3,393.39 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289680 |
| Principal investigator 1 | Ipsen Innovation | $350.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289682 |
| Principal investigator 1 | Ipsen Innovation | $1,300.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289684 |
| Principal investigator 1 | Ipsen Innovation | $50.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289686 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289688 |
| Principal investigator 1 | Ipsen Innovation | $650.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289690 |
| Principal investigator 1 | Ipsen Innovation | $978.81 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289692 |
| Principal investigator 1 | Ipsen Innovation | $3,233.23 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289696 |
| Principal investigator 1 | Ipsen Innovation | $63.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289698 |
| Principal investigator 1 | Ipsen Innovation | $86.80 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289702 |
| Principal investigator 1 | Ipsen Innovation | $3,000.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289704 |
| Principal investigator 1 | Ipsen Innovation | $1,300.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289706 |
| Principal investigator 1 | Ipsen Innovation | $350.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289710 |
| Principal investigator 1 | Ipsen Innovation | $9,100.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289712 |
| Principal investigator 1 | Ipsen Innovation | $350.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289714 |
| Principal investigator 1 | Ipsen Innovation | $9,100.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289716 |
| Principal investigator 1 | Ipsen Innovation | $3,233.23 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289718 |
| Principal investigator 1 | Ipsen Innovation | $2,350.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289720 |
| Principal investigator 1 | Ipsen Innovation | $86.80 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289722 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289724 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 10/08/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289728 |
| Principal investigator 1 | Eli Lilly and Company | $75.00 | 09/24/2025 | Non-covered Recipient Entity HOPE L. O'BRIEN | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | No dispute reported | 06/30/2026 | 1187881900 |
| Principal investigator 1 | ABBVIE INC. | $2,897.10 | 09/03/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202508264 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 08/28/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289632 |
| Principal investigator 1 | ABBVIE INC. | $395.55 | 08/05/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202502098 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 07/31/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289624 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 07/31/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289626 |
| Principal investigator 1 | Ipsen Innovation | $450.00 | 07/31/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289628 |
| Principal investigator 1 | Ipsen Innovation | $450.00 | 07/22/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289630 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 06/25/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289622 |
| Principal investigator 1 | Ipsen Innovation | $90.00 | 06/04/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289616 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 06/04/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289618 |
| Principal investigator 1 | Ipsen Innovation | $150.00 | 06/04/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289620 |
| Principal investigator 1 | ABBVIE INC. | $1,821.15 | 06/03/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202487749 |
| Principal investigator 1 | Eli Lilly and Company | $28,700.00 | 05/15/2025 | Non-covered Recipient Entity HOPE L. O'BRIEN | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | No dispute reported | 06/30/2026 | 1187883414 |
| Principal investigator 1 | Ipsen Innovation | $482.00 | 05/15/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289614 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 05/13/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289608 |
| Principal investigator 1 | Ipsen Innovation | $180.00 | 05/13/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289610 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 05/13/2025 | Non-covered Recipient Entity Headache Center Of Hope | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289612 |
| Principal investigator 1 | ABBVIE INC. | $1,595.55 | 05/06/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202481721 |
| Principal investigator 1 | Ipsen Innovation | $180.00 | 04/21/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289602 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 04/21/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289604 |
| Principal investigator 1 | Ipsen Innovation | $300.00 | 04/21/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289606 |
| Principal investigator 1 | ABBVIE INC. | $395.55 | 04/03/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202469441 |
| Principal investigator 1 | Ipsen Innovation | $482.21 | 03/25/2025 | Non-covered Recipient Entity Headache Center Of Hope | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184289600 |
| Principal investigator 1 | ABBVIE INC. | $2,404.65 | 03/06/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202456280 |
| Principal investigator 1 | ABBVIE INC. | $395.55 | 02/05/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202444811 |
| Principal investigator 1 | Eli Lilly and Company | $1,827.55 | 02/04/2025 | Non-covered Recipient Entity HOPE L. O'BRIEN | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | No dispute reported | 06/30/2026 | 1187883410 |
| Principal investigator 1 | Eli Lilly and Company | $10,242.00 | 01/28/2025 | Non-covered Recipient Entity HOPE L. O'BRIEN | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | No dispute reported | 06/30/2026 | 1187881540 |
| Principal investigator 1 | Eli Lilly and Company | $974.73 | 01/27/2025 | Non-covered Recipient Entity HOPE L. O'BRIEN | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | No dispute reported | 06/30/2026 | 1187883412 |
| Principal investigator 1 | ABBVIE INC. | $695.55 | 01/02/2025 | Non-covered Recipient Entity HEADACHE CENTER OF HOPE LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202436153 |